The presence of the APOE ε4 genotype, the main genetic risk factor for AD, does not influence the therapeutic effect of acetylcholinesterase inhibitors, but its relationship with other types of drugs is unknown (Cheng et al., 2018). The gene discussed is APOE; the disease is Alzheimer disease.